版本:
中国

BRIEF-Corvus Pharmaceuticals expands CPI-444 clinical collaboration with Genentech

May 2 Corvus Pharmaceuticals Inc:

* Corvus Pharmaceuticals expands cpi-444 clinical collaboration with Genentech

* Corvus Pharmaceuticals - Genentech will manage study operations for phase 1B/2 trial, which is expected to begin enrolling patients in second half of 2017

* Corvus Pharmaceuticals Inc - financial terms were not disclosed

* Corvus Pharmaceuticals Inc - Corvus will retain global development and commercialization rights to CPI-444

* Corvus Pharmaceuticals Inc- expanded its clinical collaboration with Genentech, a member of Roche Group

* Corvus Pharmaceuticals Inc- anticipated that randomized, controlled study will enroll up to 65 patients in treatment arm Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐